The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases

Current Vascular Pharmacology

Volumn 8, Issue 4, 2010, Pages 437-449

  Gasparyan, Armen Yuri ^a   Stavropoulos Kalinoglou, Antonios ^a   Mikhailidis, Dimitri P ^b   Toms, Tracey E ^a,c   Douglas, Karen M J ^a   Kitas, George D ^a,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atherosclerosis; Beh et's disease; Cardiovascular disease; Familial mediterranean fever; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; COLCHICINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; QUINAPRIL; RHEUMATOID FACTOR; SERUM AMYLOID A; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AMINO ACID BLOOD LEVEL; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON CAROTID ARTERY; COMORBIDITY; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; ECHOGRAPHY; FAMILIAL MEDITERRANEAN FEVER; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NEUTROPHIL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SURVIVAL; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; RESEARCH DESIGN; RHEUMATIC DISEASES; RISK FACTORS;

EID: 77953802713     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791330852     Document Type: Article

References (199)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997; 349: 1269-76.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
3. Critchley JA, Capewell S. Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. J Epidemiol Commun Health 2003; 57: 243-7.
4. Unal B, Critchley JA, Capewell S. Small changes in United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. J Clin Epidemiol 2005; 58: 733-40.
5. Kabir Z, Bennett K, Critchley JA, Capewell S. Can small changes in cardiovascular risk factors predict large future reductions in coronary heart disease mortality in Ireland? Eur J Epidemiol 2007; 22: 83-9.
6. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11: 229.
7. Tincani A, Biasini-Rebaioli C, Cattaneo R, Riboldi P. Nonorgan specific autoantibodies and heart damage. Lupus 2005; 14: 656-9.
8. Tincani A, Rebaioli C.B, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 2006; 45 (Suppl 4): iv8-13.
9. Becker-Merok A, Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus 2009; 18: 508-15.
10. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
11. Voskuyl A.E. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45 (Suppl 4): iv4-7.
12. Smolen JS, Aletaha D, Steiner G. Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 2009; 68: 159-62.
13. Tanasescu C, Jurcut C, Jurcut R, Ginghina C. Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk. Eur J Intern Med 2009; 20: 348-54.
14. Gerli R, Goodson NJ. Cardiovascular involvement in rheumatoid arthritis. Lupus 2005; 14: 679-82.
15. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11: 229.
16. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351: 659-64.
17. Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009; 76: 227-33.
18. Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci 2009; 13 (Suppl 1): 51-3.
19. Tunca M, Akar S, Onen F, et al.; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84: 1-11.
20. Ozen S. Familial mediterranean fever: revisiting an ancient disease. Eur J Pediatr 2003; 162: 449-54.
21. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behçet's disease. Clin Exp Rheumatol 2001; 19 (5 Suppl 24): S19-24.
22. Onen F. Familial Mediterranean fever. Rheumatol Int 2006; 26: 489-96.
23. Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77: 268-97.
24. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 2007; 37: 182-8.
25. Colak B, Gurlek B, Yegin ZA, et al. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial mediterranean fever. Ren Fail 2008; 30: 187-91.
26. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38: 411-9.
27. Caliskan M, Gullu H, Yilmaz S, et al. Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 2007; 195: e161-7.
28. Gasparyan A. Echocardiographic features of cardiac involvement in Familial Mediterranean Fever. Clin Exp Rheumatol 2008; 26: 192.
29. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascular involvement in familial Mediterranean fever. Arch Med Sci 2008; 4: 465-67.
30. Ishak GE, Khoury NJ, Birjawi GA, El-Zein YR, Naffaa LN, Haddad MC. Imaging findings of familial Mediterranean fever. Clin Imaging 2006; 30: 153-9.
31. Keven K, Oztas E, Aksoy H, Duman N, Erbay B, Ertürk S. Polyglandular endocrine failure in a patient with amyloidosis secondary to familial Mediterranean fever. Am J Kidney Dis 2001; 38: E39.
32. Charteris DG, Champ C, Rosenthal AR, Lightman SL. Behçet's disease: activated T lymphocytes in retinal perivasculitis. Br J Ophthalmol 1992; 76: 499-501.
33. Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum 2009; 61: 600-4.
34. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284-91.
35. Ozatli D, Kav T, Haznedaroglu IC, et al. Cardiac and great vessel thrombosis in Behçet's disease. Intern Med 2001; 40: 68-72.
36. Alpagut U, Ugurlucan M, Dayioglu E. Major arterial involvement and review of Behcet's disease. Ann Vasc Surg 2007; 21: 232-9.
37. Kiraz S, Ertenli I, Oztürk MA, Haznedaroǧlu IC, Celik I, Calgüneri M. Pathological haemostasis and prothrombotic state in Behçet's disease. Thromb Res 2002; 105: 125-33.
38. Barnes CG, Yazici H. Behçet's syndrome. Rheumatology (Oxford) 1999; 38: 1171-4.
39. Stankovic K, Grateau G. Auto inflammatory syndromes: diagnosis and treatment. Joint Bone Spine 2007; 74: 544-50.
40. Galeazzi M, Gasbarrini G, Ghirardello A, et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006; 24 (Suppl 40): S79-85.
41. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17: 586-99.
42. Ben-Chetrit E, Yazici H. Thoughts on the proposed links between Behçet's disease and familial Mediterranean fever. Clin Exp Rheumatol 2002; 20 (4 Suppl 26): S1-2.
43. Takeno M, Ishigatsubo Y. Behcet's disease and familial Mediterranean fever. Intern Med 2006; 45: 805-6.
44. Birlik M, Tunca M, Hizli N, et al. Coexistence of familial Mediterranean fever with sacroiliitis and Behçet's disease: a rare occurrence. Clin Rheumatol 1998; 17: 397-9.
45. Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A. Behçet's disease in Familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 2000; 29: 286-95.
46. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
47. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63: 952-5.
48. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 607-13.
49. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
50. Pincus T, Callahan LF. Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 1992; 41: 1-4.
51. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
52. Doria A, Arienti S, Rampudda M, Canova M, Tonon M, Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008; 7: 192-7.
53. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
54. Korkmaz C, Cansu DU, Kaşifoǧlu T. Myocardial infarction in young patients (< or =35 years of age) with systemic lupus erythematosus: a case report and clinical analysis of the literature. Lupus 2007; 16: 289-97.
55. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-73.
56. Voisin L, Derumeaux G, Borg JY, et al. Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis. J Rheumatol 1995; 22: 1586-8.
57. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28: 69-75.
58. Nazaretyan E.Y, Ayvazyan A.A. Familial Mediterranean fever as a risk factor for myocardial infarction. Clin Exp Rheumatol 2002; 20 (Suppl 26): S-86.
59. Siepmann M, Kirch W. Coronary anomaly in Behçet's syndrome. Rheumatol Int 1997; 17: 39-42.
60. Sismanoglu M, Omeroglu SN, Mansuroglu D, et al. Coronary artery disease and coronary artery bypass grafting in Behçet's disease. J Card Surg 2005; 20: 160-3.
61. Arishiro K, Nariyama J, Hoshiga M, et al. Vascular Behçet's disease with coronary artery aneurysm. Intern Med 2006; 45: 903-7.
62. Lee S, Lee CY, Yoo KJ. Acute myocardial infarction due to an unruptured sinus of Valsalva aneurysm in a patient with Behçet's syndrome. Yonsei Med J 2007; 48: 883-5.
63. Sonia H, Khaldoun BH, Sylvia M, Faouzi M, Habib G, Mohamed BF. Stenosis and aneurysm of coronary arteries in a patient with behcet's disease. Open Cardiovasc Med J 2008; 2: 118-20.
64. Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001; 3: 9-12.
65. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Behçet's Syndrome. Semin Arthritis Rheum 2008; 38: 1-12.
66. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005; 7: 1-24.
67. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
68. Simard JF, Costenbader KH, Liang MH, Karlson EW, Mittleman MA. Exposure to maternal smoking and incident SLE in a prospective cohort study. Lupus 2009; 18: 431-5.
69. Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 2003; 30: 493-6.
70. Toloza SM, Uribe AG, McGwin G Jr, et al.; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-57.
71. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007; 34: 70-5.
72. Simard JF, Costenbader KH. What can epidemiology tell us about systemic lupus erythematosus? Int J Clin Pract 2007; 61: 1170-80.
73. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195-9.
74. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39: 732-5.
75. Goodson NJ, Silman AJ, Pattison DJ, et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 2004; 43: 731-6.
76. Naranjo A, Sokka T, Descalzo MA, et al.; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: R30.
77. Gonzalez A, Maradit KH, Crowson CS. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64-9.
78. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204: 178-83.
79. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2005; 52: 722-32.
80. Soy M, Erken E, Konca K, Ozbek S. Smoking and Behçet's disease. Clin Rheumatol 2000; 19: 508-9.
81. Kaklamani VG, Markomichelakis N, Kaklamanis PG. Could nicotine be beneficial for Behçet's disease? Clin Rheumatol 2002; 21: 341-2.
82. Korkmaz C, Bozan B, Kosar M, Sahin F, Gülbas Z. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? Clin Exp Rheumatol 2002; 20 (4 Suppl 26): S30-4.
83. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
84. Choy E, Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
85. Toms T.E, Symmons D.P, Kitas G.D. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; [in press].
86. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 213.
87. Wållberg-Jonsson S, Dahlén G, Johnson O, Olivecrona G, Rantapää-Dahlqvist S. Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis. J Intern Med 1996; 240: 373-80.
88. Borba EF, Carvalho JF, Bonfá E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006; 13: 203-8.
89. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
90. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004; 31: 1746-53.
91. Georgiadis AN, Voulgari PV, Argyropoulou MI, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008; 38: 13-9.
92. Dursunoǧlu D, Evrengül H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-5.
93. John H, Kitas G, Toms T, Goodson N. Cardiovascular comorbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 71-82.
94. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994; 70: 863-70.
95. Hafström I, Rohani M, Deneberg S, Wörnert M, Jogestrand T, Frostegård J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J Rheumatol 2007; 34: 1810-6.
96. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of shortterm, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987; 63: 167-72.
97. Soubrier M, Mathieu S, Dubost JJ. Atheroma and systemic lupus erythematosus. Joint Bone Spine 2007; 74: 566-70.
98. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
99. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-63.
100. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 74-7.
101. Pereira RM, de Carvalho JF, Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8: 415-9.
102. Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a crosssectional study. Arthritis Res Ther 2008; 10: R145.
103. Baysal T, Peru H, Oran B, Sahin TK, Koksal Y, Karaaslan S. Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever. Clin Rheumatol 2009; 28: 23-8.
104. Balik O, Gur G, Lenk N, Artuz F, Alli N. Serum lipoprotein (a) levels and Behçet's disease: is there an association? Int J Dermatol 2007; 46: 827-9.
105. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12: 1623-35.
106. Pietri P, Vyssoulis G, Vlachopoulos C, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231-8.
107. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-51.
108. Li JJ, Chen JL. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005; 64: 925-9.
109. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1286-98.
110. Panoulas VF, Douglas KM, Smith JP, et al. Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 113-8.
111. Panoulas VF, Douglas KM, Smith JP, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 2008; 15: 203-12.
112. Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1477-82.
113. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 72-5.
114. Tziomalos K, Sivanadarajah N, Mikhailidis DP, Boumpas DT, Seifalian AM. Increased risk of vascular events in systemic lupus erythematosus: is arterial stiffness a predictor of vascular risk? Clin Exp Rheumatol 2008; 26: 1134-45.
115. Soltész P, Dér H, Kerekes G, et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009; 28: 655-62.
116. Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis vs. diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29(10): 1702-8.
117. Chaiamnuay S, Bertoli AM, Roseman JM, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis 2007; 66: 618-22.
118. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-5.
119. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum 2008; 58: 2612-21.
120. Erdem H, Dinc A, Pay S, Simsek I, Turan M. Peripheral insulin resistance in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2006; 20: 391-5.
121. Yildiz M, Masatlioglu S, Seymen P, Aytac E, Sahin B, Seymen HO. The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever. Can J Cardiol 2006; 22: 1127-31.
122. Protogerou AD, Lekakis J, Ikonomidis I, et al. Pressure wave reflections, central blood pressure, and aortic stiffness in patients with Adamantiades-Behcet's disease: a cross-sectional case-control study underlining the role of chronic corticosteroid treatment. Am J Hypertens 2006; 19: 660-6.
123. Protogerou AD, Achimastos A, Vlachopoulos C, et al. Reduced pressure wave reflections in patients with active clinical status of Adamantiades-Behcet disease. Hellenic J Cardiol 2008; 49: 408-14.
124. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005; 14: 736-41.
125. Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus 2008; 17: 878-87.
126. Pereira I, Laurindo I, Burlingame R, et al. Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. Joint Bone Spine 2008; 75: 416-21.
127. Goodson NJ, Wiles NJ, Lunt M, Barret EM, Silman AJ, Simmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-19.
128. Kandolf-Sekulovic L, Pavlovic MD, Glisic B, et al. Adamantiades-Behçet's disease, deep venous thrombosis and anticardiolipin antibodies: report of two cases. J Eur Acad Dermatol Venereol 2005; 19: 484-6.
129. Chen WH, Lin HS, Kao YF, Lan MY, Liu JS. Hyperhomocysteinemia relates to the subtype of antiphospholipid antibodies in non-SLE patients. Clin Appl Thromb Hemost 2007; 13: 398-403.
130. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-4.
131. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 2001; 19: 561-4.
132. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3412-9.
133. Ozdemir R, Barutcu I, Sezgin AT, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004; 94: 522-5.
134. Yesilova Z, Pay S, Oktenli C, et al. Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy? Rheumatol Int 2005; 25: 423-8.
135. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci 2009; 338: 48-9.
136. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94.
137. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008; 6: 258-70.
138. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
139. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-92.
140. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem 2009; 55: 361-4.
141. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003; 96: 793-807.
142. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
143. Fortmann SP, Ford E, Criqui MH, et al.; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation 2004; 110: e554-9.
144. Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576-82.
145. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
146. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005; 25: 2043-53.
147. del Val del Amo N, Ibanez BR, Fito MC, Gutierrez PR, Loza CE. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006; 24: 281-6.
148. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol 2007; 34: 681-8.
149. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
150. Korkmaz C, Ozdogan H, Kasapçopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61: 79-81.
151. Müftüolu AU, Yazici H, Yurdakul S, et al. Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235-9.
152. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201: 37-9.
153. Bekpinar S, Koçak H, Unlüçerçi Y, Genç S, Akdaǧ-Köse A, Göü F. The evaluation of C-reactive protein, homocysteine and vitamin B6 concentrations in Behçet and rheumatoid arthritis disease. Clin Chim Acta 2003; 329: 143-5.
154. Gasparyan AY. The use of carotid artery ultrasonography in different clinical conditions. Open Cardiovasc Med J 2009; 3: 78-80.
155. Lekakis JP, Papamichael CM, Cimponeriu AT, et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000; 85: 949-52.
156. Srámek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000; 35: 699-706.
157. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
158. Jiménez S, García-Criado MA, Tàssies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44: 756-61.
159. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-5.
160. Del Rincón I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40.
161. del Rincón I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52: 3413-23.
162. Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006; 48: 2351-3.
163. Hong SN, Park JC, Yoon NS, et al. Carotid artery intima-media thickness in Behcet's disease patients without significant cardiovascular involvement. Korean J Intern Med 2008; 23: 87-93.
164. Sari I, Karaoglu O, Can G, et al. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 2007; 26: 1467-73.
165. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford) 2009; 48: 911-5.
166. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
167. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
168. Sever P.S, Poulter N.R, Dahlöf B., Wedel H.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96: 39F-44F.
169. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-51.
170. Collins R., Armitage J., Parish S., Sleigh P., Peto R.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
171. Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J 2003; 145: 643-51.
172. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J 2007; 1: 8-14.
173. Kakafika AI, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective? Expert Opin Pharmacother 2008; 9: 1437-40.
174. Tziomalos K, Kakafika AI, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des 2009; 15: 1054-62.
175. Kakafika A, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. High density lipoprotein cholesterol and statin trials. Curr Med Chem 2008; 15: 2265-70.
176. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin 2008; 24: 1593-9.
177. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
178. Van der Hilst JC, Kluve-Beckerman B, Drenth JP, Bodar EJ, van der Meer JW, Simon A. Lovastatin inhibits formation of AA amyloid. J Leukoc Biol 2008; 83: 1295-9.
179. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008; 6: 237-9.
180. McMahon M, Brahn E. Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opin Investig Drugs 2008; 17: 1213-24.
181. Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009; 68: 453-5.
182. Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007; 25: 102-11.
183. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8: 663-7.
184. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007; 46: 1560-5.
185. Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin doseescalation study in systemic lupus erythematosus. Rheumatol Int 2007; 27: 1071-7.
186. Norby GE, Holme I, Fellström B, et al.; Assessment of Lescol in Renal Transplantation Study Group. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 2009; 60: 1060-4.
187. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-21.
188. Tikiz C, Utuk O, Pirildar T, et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005; 32: 2095-101.
189. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-8.
190. Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21: 17-24.
191. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol 2007; 13: 266-8.
192. Hashimoto T, Toya Y, Kihara M, et al. Behçet's disease complicated by IgA nephropathy with nephrotic syndrome. Clin Exp Nephrol 2008; 12: 224-7.
193. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005; 25: 1213-29.
194. Teplitsky V, Shoenfeld Y, Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 2006; 15: 319-25.
195. Martínez-González J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007; 13: 2215-27.
196. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-43.
197. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L.; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
198. Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746-50.
199. Grimaldi MP, Candore G, Vasto S, et al. Role of the pyrin M694V (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population. J Leukoc Biol 2006; 79: 611-5.